FDA cites Avaria Health & Beauty for manufacturing-rule violations in OTC drugs, including missing glycerin identity testing and weak quality unit.
What happened
FDA reviewed records Avaria submitted after FDA's January 25, 2023 request for records under federal law; this was a records review, not an inspection. FDA found the company did not test each shipment and lot of high-risk components such as glycerin for identity, including a standard test for diethylene glycol (DEG) and ethylene glycol (EG), and that its quality unit did not adequately approve or reject components. FDA placed the firm on Import Alert 66-40, which can stop U.S. imports, on April 14, 2023.
What FDA found
Avaria did not test each shipment and lot of high-risk incoming components, including glycerin, for identity with the test that detects DEG and EG.
21 CFR 211.84(d)(1)Avaria's quality unit did not effectively use its authority to approve or reject components in its materials system.
21 CFR 211.22(a)
What FDA wants
FDA tells Avaria to respond in writing within 30 working days with corrective actions, including DEG and EG test results within 30 calendar days, a risk assessment for in-date products, component testing plans, and quality-unit remediation. If corrective actions cannot be completed in 15 working days, the company must explain the delay and give a completion schedule.
Who should pay attention
- brands that buy OTC drugs or hand sanitizer from this contract manufacturer
- companies using glycerin or other high-risk components in drug products
- U.S. importers and distributors of Avaria products
This is a summary. Read the original letter on fda.gov.